Literature DB >> 26498085

Re: Yeh et al.: Ophthalmic Technology Assessment: therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology (Ophthalmology 2015;122:769-78).

Dan Călugăru1, Mihai Călugăru2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26498085     DOI： 10.1016/j.ophtha.2015.02.043

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  5 in total

1.  Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-10-18       Impact factor: 3.117

2.  Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.

Authors:  D Călugăru; M Călugăru
Journal:  Eye (Lond)       Date:  2017-03-17       Impact factor: 3.775

3.  Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-21       Impact factor: 3.117

4.  Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-04       Impact factor: 3.117

Review 5.  Bevacizumab in the treatment of acute central/hemicentral retinal vein occlusions.

Authors:  Dan Călugăru; Mihai Călugăru; Ștefan Țălu
Journal:  Rom J Ophthalmol       Date:  2016 Jul-Sep
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.